Role of Vaginal Microbiota Dysbiosis in Gynecological Diseases and the Potential Interventions

Han, Yiwen; Li, Zhaoxia; Chen, Tingtao

doi:10.3389/fmicb.2021.643422

Cited by 59 publications

(57 citation statements)

References 108 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It should be emphasized that the vagino–uterine microbiota and its dysbiosis may influence the pathogenesis of several gynecological infectious and non-infectious illnesses [ 18 , 20 , 102 ], including gynecologic cancers [ 103 ]. Recently, it was observed that dysbiosis of the vaginal microbiome may be involved in recurrent implantation failure (RIF) at various stages, such as formation of gametes, implantation, and delivery [ 18 , 104 ].…”

Section: Vaginal and Endometrial Microbiome (Microbiota) Disturbancesmentioning

confidence: 99%

See 1 more Smart Citation

Biomolecular Markers of Recurrent Implantation Failure—A Review

Mrozikiewicz

Ożarowski

Jȩdrzejczak

2021

IJMS

View full text Add to dashboard Cite

Currently, infertility affects 8–12% of reproductive age couples worldwide, a problem that also affects women suffering from recurrent implantation failure (RIF). RIF is a complex condition resulting from many physiological and molecular mechanisms involving dynamic endometrium–blastocyst interaction. The most important are the endometrial receptivity process, decidualization, trophoblast invasion, and blastocyst nesting. Although the exact multifactorial pathogenesis of RIF remains unclear, many studies have suggested the association between hormone level imbalance, disturbances of angiogenic and immunomodulatory factors, certain genetic polymorphisms, and occurrence of RIF. These studies were performed in quite small groups. Additionally, the results are inconsistent between ethnicities. The present review briefly summarizes the importance of factors involved in RIF development that could also serve as diagnostic determinants. Moreover, our review could constitute part of a new platform for discovery of novel diagnostic and therapeutic solutions for RIF.

show abstract

Section: Vaginal and Endometrial Microbiome (Microbiota) Disturbancesmentioning

confidence: 99%

“…Uterine anatomical abnormalities (bicornal uterus, uterine septa, myomas, endometrial polyps, intrauterine adhesions) [8] immunological (HLA, NK cells, TK cells) [9,10] biomolecular (p53, LIF) [11][12][13][14] glycodelin-A [15][16][17] infection [18][19][20] Table 1. Cont.…”

Section: Risk Factors Of Rif Referencesmentioning

confidence: 99%

Biomolecular Markers of Recurrent Implantation Failure—A Review

Mrozikiewicz

Ożarowski

Jȩdrzejczak

2021

IJMS

View full text Add to dashboard Cite

show abstract

“…2,6,7 Vaginal microbiota dysbiosis, characterized by the loss of lactobacilli dominance and increase of microbial diversity, is closely related to gynecological diseases. 8 Among these, bacterial vaginosis (BV) is associated with an excessive growth of diverse, predominantly anaerobic bacteria including Gardnerella, Prevotella, Atopobium, Mobiluncus, and Sneathia, 9 as well as a decrease in lactic acid and hydrogen peroxide concentration resulting in an increase in vaginal pH. 10 BV is often diagnosed by a gramstain based Nugent score (NS) of 7-10, 11 as well as via Amsel's criteria, point-of-care, 12 and more recently, molecular tests.…”

Section: Introductionmentioning

confidence: 99%

Effects of a 10-Strain Oral Probiotic on Parameters of Vaginal Health and Microbial Community: A Pilot Clinical Study

CJ¹,

AKS²,

Damholt³

et al. 2022

IJWH

View full text Add to dashboard Cite

Objective To investigate the clinical effects of a 10-strain probiotic on parameters of vaginal health in a pilot, open label study in women with intermediate Nugent score (NS) or vaginal pH >4.5. Methodology A total of 43 healthy premenopausal women, ages 18 to 50 years, with NS of 4–6 or vaginal pH >4.5 were enrolled. Participants consumed a probiotic formulation (Feminine Support™), containing 8 lactobacilli and 2 bifidobacteria strains, with a daily dose of 2.5×10 10 CFU for 28 (subgroup 1) or 42 (subgroup 2) days. Investigational visits occurred at day 0, 14, 28 and 42 with assessment of vaginal pH, NS and vaginal microbiota, via next-generation sequencing. Results A total of 36 participants were included in the analysis set, with 24 and 12 participants included in subgroups 1 and 2, respectively. In the analysis set, there was a significant reduction in vaginal pH, from baseline, at day 28 (mean change=−0.19, P = 0.047). Participants in subgroup 1 achieved a significant reduction in vaginal pH from baseline, at day 28 (mean change=−0.23, P = 0.029) and day 42 (mean change=−0.29, P = 0.008), while participants in subgroup 2 achieved a significant and quantitatively greater reduction in vaginal pH from baseline to day 42 (mean change=−0.64, P = 0.008). No significant changes in NS were reported, due in part to highly diverse baseline levels. Vaginal microbial abundance exhibited a majority lactobacilli abundance at baseline, which was maintained over the study period. Vaginal pH was inversely associated with lactobacilli abundance throughout the study (P < 0.005). The product was well tolerated with high compliance. Two participants reported adverse events with suspected causality, which were mild and resolved during the study. Conclusion This 10-strain probiotic formulation was well tolerated and helped reduce vaginal pH in women with intermediate NS or elevated vaginal pH. The study product warrants a randomized controlled trial to further assess efficacy.

show abstract

“…FMT contains the microbiome, which is critical in maintaining homeostasis and health. Microbiota dysbiosis is also responsible for gynecological cancer [ 263 , 264 , 265 ]. Epidemiological studies indicate that the urogenital microbiota dysbiosis is implied in gynecological cancers, particularly cervical cancer [ 263 , 264 , 266 ].…”

Section: Gut Microbiota and Cancer Therapy Efficacymentioning

confidence: 99%

“…Microbiota dysbiosis is also responsible for gynecological cancer [ 263 , 264 , 265 ]. Epidemiological studies indicate that the urogenital microbiota dysbiosis is implied in gynecological cancers, particularly cervical cancer [ 263 , 264 , 266 ]. Probiotics or microbiota transplant seems to be effective in improving responsiveness to treatment of gynecological cancer [ 263 , 267 , 268 ].…”

Section: Gut Microbiota and Cancer Therapy Efficacymentioning

confidence: 99%

Harness the functions of gut microbiome in tumorigenesis for cancer treatment

Lee

2021

Cancer Communications

View full text Add to dashboard Cite

It has been shown that gut microbiota dysbiosis leads to physiological changes and links to a number of diseases, including cancers. Thus, many cancer categories and treatment regimens should be investigated in the context of the microbiome. Owing to the availability of metagenome sequencing and multiomics studies, analyses of species characterization, host genetic changes, and metabolic profile of gut microbiota have become feasible, which has facilitated an exponential knowledge gain about microbiota composition, taxonomic alterations, and host interactions during tumorigenesis. However, the complexity of the gut microbiota, with a plethora of uncharacterized host‐microbe, microbe‐microbe, and environmental interactions, still contributes to the challenge of advancing our knowledge of the microbiota‐cancer interactions. These interactions manifest in signaling relay, metabolism, immunity, tumor development, genetic instability, sensitivity to cancer chemotherapy and immunotherapy. This review summarizes current studies/molecular mechanisms regarding the association between the gut microbiota and the development of cancers, which provides insights into the therapeutic strategies that could be harnessed for cancer diagnosis, treatment, or prevention.

show abstract

Role of Vaginal Microbiota Dysbiosis in Gynecological Diseases and the Potential Interventions

Cited by 59 publications

References 108 publications

Biomolecular Markers of Recurrent Implantation Failure—A Review

Biomolecular Markers of Recurrent Implantation Failure—A Review

Effects of a 10-Strain Oral Probiotic on Parameters of Vaginal Health and Microbial Community: A Pilot Clinical Study

Harness the functions of gut microbiome in tumorigenesis for cancer treatment

Contact Info

Product

Resources

About